Endocrine Abstracts

BackgroundPrevalence of hypogonadism has been reported as high as 50% in men with T2DM and/or obesity. ADA and AACE Guidelines recommend assessment of hypogonadism in men with T2DM and obesity.Material and methodsIn a registry of 865 men with hypogonadism, 361 men (41.7%) had T2DM. 183 received TU 1000 mg/12 weeks (T-group), 178 opted against treatment (CTRL). Changes over time between groups were compared an...

BackgroundWhile almost all studies consistently show reduction of waist circumference as a result of testosterone therapy (TTh), effects on body weight are inconsistent and may depend on treatment duration, route of administration, and adherence.Material and methodsAfter excluding men with primary hypogonadism, 476 men with functional, symptomatic hypogonadism were obese. 281 men received testosterone undecan...

BackgroundEffects of testosterone therapy (TTh) on lipid parameters are inconsistent and may depend on treatment duration, route of administration, and adherence. While in short-term studies, testosterone usually lowers HDL, long-term studies seem to increase HDL. Total cholesterol, LDL and triglycerides are either reduced by TTh, or effects are neutral.Material and methodsAfter excluding men with primary hyp...